Department of Radiation Oncology, University Hospital and Medical Faculty, Eberhard Karls University, Tübingen, Germany; German Cancer Consortium (DKTK), Partner Site Tübingen, and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Department of Radiation Oncology, University Hospital and Medical Faculty, Eberhard Karls University, Tübingen, Germany.
Radiother Oncol. 2021 Nov;164:37-42. doi: 10.1016/j.radonc.2021.09.002. Epub 2021 Sep 14.
Dose escalated radiotherapy has previously been investigated as a strategy to increase complete response rates in rectal cancer. However large safety margins are required using cone-beam computed tomography guided radiotherapy leading to high doses to organs at risk or insufficient target volume coverage in order to keep dose constraints. We herein present the first clinical application of a new technique for dose escalation in rectal cancer using online magnetic resonance (MR)-guidance and rectal ultrasound gel filling.
A 73-year-old patient with distal cT3a cN0 cM0 rectal cancer was referred for definitive radiochemotherapy with the goal of organ preservation after multidisciplinary discussion. A dose of 45 Gy in 25 fractions with a stereotactic integrated boost to the primary tumor of 50 Gy with concomitant 5-fluorouracil was prescribed. Furthermore, a boost to the primary tumor with 3 Gy per fraction using the adapt-to-shape workflow on a 1.5 T MR-Linac was planned once weekly. For the boost fractions 100 cc of ultrasound gel was applied rectally in order to improve tumor visibility and distancing of uninvolved rectal mucosa. In order to determine the required planning target volume margin diagnostic scans of ten rectal cancer patients conducted with rectal ultrasound gel filling were studied.
Based on the ten diagnostic scans an average isotropic margin of 4 mm was found to be sufficient to cover 95% of the target volume during an online adaptive workflow. Three boost fractions were applied, mean treatment duration was 22:34 min. Treatment was well tolerated by the patient with no more than PRO-CTCAE grade I° toxicity of any kind. The rectal ultrasound gel filling resulted in superior visibility of the tumor and reduced the dose to the involved mucosa especially in the high dose range compared with a boost plan calculated without any filling. A considerable tumor shrinkage was observed during treatment from 17.43 cc at baseline to 4 cc in week four.
This novel method appears to be a simple but effective strategy for dose escalated radiotherapy in rectal cancer. Based on the encouraging observation, a prospective trial is currently under preparation.
以前已经研究过递增剂量放疗作为提高直肠癌完全缓解率的策略。然而,使用锥形束计算机断层扫描引导放疗需要很大的安全裕度,这导致危及器官的高剂量或靶体积覆盖不足,以保持剂量限制。本文介绍了一种新的直肠癌递增剂量技术的首次临床应用,该技术使用在线磁共振(MR)引导和直肠超声凝胶填充。
一名 73 岁的患者患有远端 cT3a cN0 cM0 直肠癌,经多学科讨论后,建议进行放化疗以保留器官。规定给予 45 Gy/25 次分割剂量,立体定向综合 boost 至原发肿瘤 50 Gy,同时给予 5-氟尿嘧啶。此外,还计划每周使用 1.5T MR-Linac 的适形到形状工作流程对原发肿瘤进行 3Gy/次的 boost。为了提高肿瘤的可见度和未受累直肠粘膜的距离,在 boost 分数中直肠内应用 100cc 超声凝胶。为了确定所需的计划靶区边缘,研究了十例直肠癌患者在直肠超声凝胶填充下进行的诊断性扫描。
基于十次诊断性扫描,发现平均各向同性边缘为 4mm 即可在在线自适应工作流程中覆盖 95%的靶体积。应用了三个 boost 分数,平均治疗时间为 22:34 分钟。患者耐受性良好,没有任何一种 PRO-CTCAE Ⅰ°毒性。与没有任何填充的 boost 计划相比,直肠超声凝胶填充可显著提高肿瘤的可见度,降低受累粘膜的剂量,尤其是在高剂量范围内。在治疗期间观察到肿瘤明显缩小,从基线时的 17.43cc 缩小到第四周时的 4cc。
这种新方法似乎是一种简单但有效的直肠癌递增剂量放疗策略。基于令人鼓舞的观察结果,目前正在准备一项前瞻性试验。